Breaking | Hillgene Was Accepted as a Candidate of the “Unicorn” Enterprises Fostering Program

Science and technology are the primary productive forces. National and regional development cannot be separated from scientific and technological innovation. In order to implement the innovation-driven development strategy in depth, accelerate the creation of industrial scientific and technological innovation highland and high-level innovative cities, we will strive to promote a group of innovative enterprises with disruptive innovation, explosive growth, outstanding competitive advantages and large future output value to accelerate their growth into unicorn enterprises, and form iconic industries represented by unicorn enterprises.

Suzhou has launched the "Suzhou Unicorn Enterprise Cultivation Plan (2018-2022)". Spectrum Biopharmaceuticals has been selected into the Suzhou "Unicorn" Cultivation Enterprise Selection Project Acceptance List for its technical strength and development potential in the field of cell therapy.

Spectrum Biopharma has profound technical accumulation in the field of cell therapy, and its sales performance has set new records. Spectrum Biopharma is deeply trusted by customers for its excellent technology, has seized the market opportunity, has multiple successful IND filing experiences, and has hundreds of experiences in the production and preparation of clinical samples for cell therapy.

谱新生物自Since its establishment in 2020, it has completed financing of over 100 million yuan, and has its headquarters in Suzhou (10,000m2 GMP plant and R&D center), bases in Shenzhen and Shanghai, and has initially formed a nationwide production base network layout; the company has supported multiple partners to successfully incubate a number of CAR-T, TCR-T, stem cell and other drugs, and has won the first domestic commercial production order for cell production under the MAH system, officially opening the door to a new cooperation model in the field of cell drugs.

This selection is a high recognition of the innovation vitality and growth potential of Spectrum Biotech by competent departments and experts at all levels. In the future, Spectrum Biotech will seize the major development opportunities of the biopharmaceutical industry and the cell therapy segment, do a good job in strengthening its service capabilities, give full play to its professional and focused CDMO capabilities, and move towards higher goals.

Spectrum Biotech is committed to enabling more projects to reach the next milestone earlier and faster, bringing more cell drugs to the market, benefiting more patients, and allowing cell drugs to write a new chapter in life.